Understanding the regulation of pattern recognition receptors in inflammatory diseases – a ‘Nod’ in the right direction

Immunology

Volumn 150, Issue 3, 2017, Pages 237-247

  Feerick, Claire L ^a   McKernan, Declan P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

inflammation; inflammatory bowel disease; NLR expression; NOD1; NOD2

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TRIPARTITE MOTIF PROTEIN; TRIPARTITE MOTIF PROTEIN 27; UNCLASSIFIED DRUG;

AUTOPHAGY; BACTERIAL STRAIN; CHRONIC INFLAMMATION; CROHN DISEASE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HELICOBACTER HEPATICUS; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS; ANIMAL; GENETIC POLYMORPHISM; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM;

ANIMALS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; NLR PROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 85006356511     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12677     Document Type: Review

References (109)

1. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21:317–37.
2. Franchi L, et al. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227:106–28.
3. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27:549–59.
4. Ting JP, et al. The NLR gene family: a standard nomenclature. Immunity 2008; 28:285–7.
5. Inohara N, et al. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 2001; 276:2551–4.
6. Ogura Y, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001; 276:4812–8.
7. Proell M, et al. The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS One 2008; 3:e2119.
8. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26:447–54.
9. Said-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. Biomed J 2012; 35:437–49.
10. Inohara N, et al. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74:355–83.
11. Chen G, et al. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009; 4:365–98.
12. Chamaillard M, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4:702–7.
13. Girardin SE, et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003; 300:1584–7.
14. Girardin SE, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869–72.
15. Inohara N, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn′s disease. J Biol Chem 2003; 278:5509–12.
16. Iyer JK, Coggeshall KM. Cutting edge: primary innate immune cells respond efficiently to polymeric peptidoglycan, but not to peptidoglycan monomers. J Immunol 2011; 186:3841–5.
17. Schaffler H, et al. NOD2 stimulation by Staphylococcus aureus-derived peptidoglycan is boosted by Toll-like receptor 2 costimulation with lipoproteins in dendritic cells. Infect Immun 2014; 82:4681–8.
18. Fiocca R, et al. Release of Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and budding of outer membrane vesicles. Uptake of released toxin and vesicles by gastric epithelium. J Pathol 1999; 188:220–6.
19. Lee J, et al. pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J Biol Chem 2009; 284:23818–29.
20. Viala J, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5:1166–74.
21. Vavricka SR, et al. hPepT1 transports muramyl dipeptide, activating NF-κB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004; 127:1401–9.
22. Kasper CA, et al. Cell–cell propagation of NF-κB transcription factor and MAP kinase activation amplifies innate immunity against bacterial infection. Immunity 2010; 33:804–16.
23. Hahn JS. Regulation of Nod1 by Hsp90 chaperone complex. FEBS Lett 2005; 579:4513–9.
24. Lee K-H, et al. Proteasomal degradation of Nod2 protein mediates tolerance to bacterial cell wall components. J Biol Chem 2012; 287:39800–11.
25. Mohanan V, Grimes CL. Hsp70 binds to and stabilizes Nod2, an innate immune receptor involved in Crohn's disease. J Biol Chem 2014; 289:18987–98.
26. Hsu LC, et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA 2008; 105:7803–8.
27. Park JH, et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007; 178:2380–6.
28. Hasegawa M, et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. EMBO J 2008; 27:373–83.
29. DiDonato JA, et al. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997; 388:548–54.
30. Yamaoka S, et al. Complementation cloning of NEMO, a component of the IκB kinase complex Essential for NF-κB activation. Cell 1998; 93:1231–40.
31. Shaw MH, et al. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 2008; 20:377–82.
32. Vandenabeele P, Bertrand MJ. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat Rev Immunol 2012; 12:833–44.
33. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474:298–306.
34. Verma R, Verma N, Paul J. Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level. Eur Cytokine Netw 2013; 24:130–8.
35. Maglinte DD, et al. Classification of small bowel Crohn's subtypes based on multimodality imaging. Radiol Clin North Am 2003; 41:285–303.
36. Ogura Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603–6.
37. Hugot J-P, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599–603.
38. Russell RK, Nimmo ER, Satsangi J. Molecular genetics of Crohn's disease. Curr Opin Genet Dev 2004; 14:264–70.
39. Hugot J-P, et al. Prevalence of CARD15//NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 2007; 102:1259–67.
40. Kim Y-G, et al. Cutting edge: Crohn's disease-associated Nod2 mutation limits production of proinflammatory cytokines to protect the host from Enterococcus faecalis-induced lethality. J Immunol 2011; 187:2849–52.
41. Ogura Y, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003; 52:1591–7.
42. Frank DN, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17:179–84.
43. Wehkamp J, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 2004; 53:1658–64.
44. Wehkamp J, et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102:18129–34.
45. Simms LA, et al. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008; 57:903–10.
46. Ferreira CM, et al. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res 2014; 2014:12.
47. Seksik P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52:237–42.
48. Ott SJ, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53:685–93.
49. Manichanh C, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55:205–11.
50. Jia W, et al. Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. FEMS Immunol Med Microbiol 2012; 65:55–68.
51. Rehman A, et al. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011; 60:1354–62.
52. Biswas A, Petnicki-Ocwieja T, Kobayashi KS. Nod2: a key regulator linking microbiota to intestinal mucosal immunity. J Mol Med (Berl) 2012; 90:15–24.
53. Ramanan D, et al. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity 2014; 41:311–24.
54. Petnicki-Ocwieja T, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009; 106:15813–8.
55. Hold GL, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014; 20:1192–210.
56. Patel KK, Stappenbeck TS. Autophagy and intestinal homeostasis. Annu Rev Physiol 2013; 75:241–62.
57. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010; 221:3–12.
58. Homer CR, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 2010; 139: 1630–41, 1641 e1-2.
59. Travassos LH, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55–62.
60. Saitoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 2008; 456:264–8.
61. Cooney R, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90–7.
62. Sorbara MT, et al. The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner. Immunity 2013; 39:858–73.
63. Wolfkamp SC, et al. ATG16L1 and NOD2 polymorphisms enhance phagocytosis in monocytes of Crohn's disease patients. World J Gastroenterol 2014; 20:2664–72.
64. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985; 107:689–93.
65. Tromp G, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996; 59:1097–107.
66. Miceli-Richard C, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29:19–20.
67. Dugan J, et al. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. J Immunol 2015; 194:349–57.
68. Ospelt C, et al. Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:355–63.
69. Yokota K, et al. The pattern-recognition receptor nucleotide-binding oligomerization domain-containing protein 1 promotes production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2012; 64:1329–37.
70. Franca R., et al. Expression and activity of NOD1 and NOD2/RIPK2 signalling in mononuclear cells from patients with rheumatoid arthritis. Scand J Rheumatol 2015; 45:8–12.
71. Bogefors J, et al. Nod1, Nod2 and Nalp3 receptors, new potential targets in treatment of allergic rhinitis? Allergy 2010; 65:1222–6.
72. Hu S, et al. The expression of NOD1 and NOD2 and the regulation of glucocorticoids on them in allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013; 27:393–6.
73. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115–26.
74. Hamzaoui K, et al. NOD2 is highly expressed in Behcet disease with pulmonary manifestations. J Inflamm 2012; 9:3.
75. Nishio H, et al. Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol 2011; 31:1093–9.
76. −/− mice. J Immunol 2015; 194:773–80.
77. Liu H-Q, et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33:2193–201.
78. Zhao L, et al. NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2011; 301:E587–98.
79. Grundy SM, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735–52.
80. Zhou Y-J, et al. Increased NOD1, but not NOD2, activity in subcutaneous adipose tissue from patients with metabolic syndrome. Obesity 2015; 23:1394–400.
81. Lappas M. NOD1 expression is increased in the adipose tissue of women with gestational diabetes. J Endocrinol 2014; 222:99–112.
82. Hitotsumatsu O, et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008; 28:381–90.
83. Billmann-Born S, et al. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC. J Immunol 2011; 186:4027–38.
84. Musone SL, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011; 12:176–82.
85. Barmada MM, et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004; 10:513–20.
86. Bradbury LA, Brown MA. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661–78.
87. Arsenescu R, et al. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol 2008; 1:399–411.
88. Vereecke L, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010; 207:1513–23.
89. Lee EG, et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 2000; 289:2350–4.
90. Zhang R, et al. The E3 ligase RNF34 is a novel negative regulator of the NOD1 pathway. Cell Physiol Biochem 2014; 33:1954–62.
91. Yang L, et al. PSMA7 directly interacts with NOD1 and regulates its function. Cell Physiol Biochem 2013; 31:952–9.
92. Zurek B, et al. TRIM27 negatively regulates NOD2 by ubiquitination and proteasomal degradation. PLoS One 2012; 7:e41255.
93. McDonald C, et al. A role for erbin in the regulation of Nod2-dependent NF-κB signaling. J Biol Chem 2005; 280:40301–9.
94. Kufer TA, et al. Role for erbin in bacterial activation of Nod2. Infect Immun 2006; 74:3115–24.
95. Richmond AL, et al. The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology 2012; 142: 1483–92 e6.
96. von Kampen O, et al. Caspase recruitment domain-containing protein 8 (CARD8) negatively regulates NOD2-mediated signaling. J Biol Chem 2010; 285:19921–6.
97. Liu J, et al. Association between CARD8 rs2043211 polymorphism and inflammatory bowel disease: a meta-analysis. Immunol Invest 2015; 44:253–64.
98. Paramel GV, et al. CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation. Clin Sci (Lond) 2013; 125:401–7.
99. Hisamatsu T, Suzuki M, Podolsky DK. Interferon-γ augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells. J Biol Chem 2003; 278:32962–8.
100. Beg AA, et al. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol Cell Biol 1993; 13:3301–10.
101. Gutierrez O, et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem 2002; 277:41701–5.
102. Rosenstiel P, et al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124:1001–9.
103. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978; 14:105–13.
104. Leung C-H, et al. Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan. Eur J Immunol 2009; 39:3529–37.
105. Scheppach W, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103:51–6.
106. Konsoula Z, Barile FA. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods 2012; 66:215–20.
107. Acevedo N, et al. Age-associated DNA methylation changes in immune genes, histone modifiers and chromatin remodeling factors within 5 years after birth in human blood leukocytes. Clin Epigenetics 2015; 7:34.
108. Karouzakis E, et al. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 2011; 12:643–52.
109. Yamada Y, et al. Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation. Int J Mol Med 2014; 33:1355–63.